Hoth Therapeutics (HOTH) faces Nasdaq $1 bid-price deficiency and delisting risk

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Hoth Therapeutics received a notice from Nasdaq that its common stock no longer meets the exchange’s minimum bid price requirement of $1.00 per share, after trading below that level for 30 consecutive business days ending April 29, 2026.

The company has 180 calendar days, until October 27, 2026, to regain compliance by achieving a closing bid of at least $1.00 for a minimum of 10 consecutive business days. If it qualifies, Hoth may receive an additional 180-day grace period and could appeal any delisting decision. The company plans to monitor its share price and may consider actions such as a reverse stock split to meet Nasdaq listing standards.

Positive

None.

Negative

Nasdaq bid-price noncompliance and delisting risk: Hoth Therapeutics no longer meets Nasdaq’s $1.00 minimum bid requirement after 30 consecutive business days below that level, triggering a 180-day remediation window and potential further steps toward delisting if compliance is not regained.

Insights

Nasdaq bid-price deficiency creates real delisting risk if Hoth cannot lift its share price.

Hoth Therapeutics has fallen out of compliance with Nasdaq’s $1.00 minimum bid requirement after 30 consecutive business days below that level. This deficiency notice does not immediately affect trading, but it formally starts a defined remediation timeline.

The company has 180 days, until October 27, 2026, to post a closing bid of at least $1.00 for 10 consecutive business days. If other listing standards are met, Nasdaq may grant a second 180-day period. Failing both, a delisting notice would follow, with an option to appeal.

Management explicitly notes it may consider a reverse stock split to restore compliance, a common mechanical fix that does not change underlying value. Actual impact on shareholders will depend on whether Hoth can sustain the required bid price over the specified compliance windows.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice or transferred its listing to a different exchange.

Key Figures

Nasdaq minimum bid price: $1.00 per share Deficiency measurement period: 30 consecutive business days Initial compliance window: 180 calendar days +2 more

5 metrics

Nasdaq minimum bid price $1.00 per share Required under Nasdaq Listing Rule 5550(a)(2)

Deficiency measurement period 30 consecutive business days Closing bids between March 18, 2026 and April 29, 2026

Initial compliance window 180 calendar days Until October 27, 2026 to regain bid-price compliance

Compliance trading requirement 10 consecutive business days Closing bid must be at least $1.00 per share

Potential extended window Additional 180 days May be granted if other listing standards are met

Key Terms

Nasdaq Listing Rule 5550(a)(2), minimum bid price, continued listing requirements, reverse stock split, +1 more

5 terms

Nasdaq Listing Rule 5550(a)(2) regulatory

"it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2)"

minimum bid price financial

"Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share"

The minimum bid price is the lowest share price that a market, regulator, or specific offering will accept for a trade, listing, or auction—think of it as a reserve or floor that a stock must meet to qualify for certain actions. It matters to investors because falling below that floor can limit trading options, trigger compliance measures or delisting risks, and affect liquidity and the perceived value of a holding, much like a reserve price in an auction sets the baseline for a sale.

continued listing requirements regulatory

"so long as the Company meets The Nasdaq Capital Market continued listing requirements (except for the bid price requirement)"

Rules a stock exchange sets that a publicly traded company must keep meeting to stay listed and tradable on that exchange, such as minimum share price, market value, timely financial reports, and basic governance practices. Like a club’s membership rules, they matter because falling short can lead to warnings, penalties or removal from the exchange, which can cut liquidity, hurt share value and increase the risk for investors.

reverse stock split financial

"including, but not limited to, implementing a reverse stock split of its outstanding securities"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

Hearings Panel regulatory

"the Company will have an opportunity to appeal the delisting determination to a Hearings Panel"

A hearings panel is a small group of officials or experts who hold formal sessions to review evidence, question parties, and make decisions about regulatory compliance, discipline, or approvals. Think of it like a review board or courtroom for business and market issues: its findings can lead to fines, changes in a company’s permissions, or even delisting. Investors pay attention because the panel’s rulings can directly affect a company’s operations, reputation and share price.

Understanding 8-K Material Events →

05/04/2026 - 05:25 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) April 30, 2026

Hoth Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Nevada		001-38803		82-1553794
(State or other jurisdiction of incorporation)		(Commission File Number)		(I. R. S. Employer Identification No.)

720 Monroe Street, Suite E514

Hoboken, NJ 07030

(Address of principal executive offices, including ZIP code)

(866) 239-7459

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.0001 par value		HOTH		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On April 30, 2026, Hoth Therapeutics, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s common stock between March 18, 2026 and April 29, 2026, the Company no longer meets the minimum bid price requirement. The Notification Letter has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market and, at this time, the common stock will continue to trade on The Nasdaq Capital Market under the symbol “HOTH.”

The Notification Letter provides that the Company has 180 calendar days, or until October 27, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company's common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by October 27, 2026, an additional 180 days may be granted to regain compliance, so long as the Company meets The Nasdaq Capital Market continued listing requirements (except for the bid price requirement) and notifies Nasdaq in writing of its intention to cure the deficiency during the second compliance period. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, then Nasdaq will notify the Company of its determination to delist the Company's common stock, at which point the Company will have an opportunity to appeal the delisting determination to a Hearings Panel.

The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.

-1-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 4, 2026	Hoth Therapeutics, Inc.

	/s/ Robb Knie
	Robb Knie
	Chief Executive Officer

-2-

Source: View Original Filing on SEC EDGAR

FAQ

What did Hoth Therapeutics (HOTH) disclose about its Nasdaq listing status?

Hoth Therapeutics disclosed it received a Nasdaq notice that its common stock no longer meets the $1.00 minimum bid price requirement. The stock traded below this level for 30 consecutive business days, triggering a formal deficiency under Nasdaq Listing Rule 5550(a)(2).

How long does Hoth Therapeutics have to regain Nasdaq bid-price compliance?

Hoth Therapeutics has 180 calendar days, until October 27, 2026, to regain compliance. The stock must close at or above $1.00 per share for at least 10 consecutive business days during this period for Nasdaq to deem the requirement satisfied.

Can Hoth Therapeutics receive more time beyond October 27, 2026?

Nasdaq may grant Hoth Therapeutics an additional 180-day compliance period if it meets all other Nasdaq Capital Market continued listing requirements and notifies Nasdaq of its intent to cure the bid-price deficiency, giving the company potentially up to 360 days total.

What happens if Hoth Therapeutics still fails to meet Nasdaq’s bid-price rule?

If Hoth Therapeutics cannot regain compliance within the allowed periods, Nasdaq will notify the company of its determination to delist the common stock. Hoth would then have an opportunity to appeal that delisting determination to a Nasdaq Hearings Panel for further review.

Is Hoth Therapeutics’ stock still trading on Nasdaq after the deficiency notice?

Yes. The notice has no immediate effect on trading, and Hoth Therapeutics’ common stock continues to trade on The Nasdaq Capital Market under the symbol HOTH. The notice mainly starts the clock for the company to correct the bid-price deficiency.

What steps might Hoth Therapeutics consider to regain Nasdaq compliance?

Hoth Therapeutics states it plans to monitor the closing bid price of its common stock and may consider available options, including a potential reverse stock split of its outstanding securities, to restore compliance with Nasdaq’s $1.00 minimum bid price requirement.

Filing Exhibits & Attachments

3 documents